Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus

ABSTRACT

The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-α comprising an effective amount of a TNF-α inhibitor, as well as a method for treatment of such disorders, and the use of TNF-α inhibitors in the preparation of pharmaceutical compositions for such treatment.

CONTINUING APPLICATION DATA

This application is a Continuation of International Application No.PCT/SE99/01671 filed on Sep. 23, 1999 that designates the United Statesof America and was published under PCT Article 21(2) in English andclaims benefit of Swedish Applications 9803276-6 and 9803710-4 filedrespectively on Sep. 25, 1998 and Oct. 29, 1998. These applications areincorporated by reference in their entirety.

DESCRIPTION

Technical Field

The present invention relates to the use of a TNF-α inhibitor in thepreparation of pharmaceutical compositions for the treatment of nerveroot injury, as well as a method for treating nerve root injury.

The object of the present invention is to obtain a possibility to treatnerve root injury induced by disk herniation, which may turn up asradiating pain into the arm or leg (sciatica), by blocking disk relatedcytokines.

BACKGROUND OF THE INVENTION

Disk herniation is a troublesome disorder, which can cause pronouncedpain and muscle dysfunction, and thereby loss of ability to work. Aherniation may occur in any disk in the spine but herniations in thelumbar and the cervical spine are most common. A disk herniation in thecervical spine may induce radiating pain and muscle dysfunction in thearm and herniation in the lumbar spine may induce radiating pain andmuscle dysfunction in the leg. The radiating pain in the leg isgenerally referred to a “sciatica”. Disk herniation will cause troubleto a varying degree, and the pain may last for one or two months or insevere cases up to 6 months. The arm or leg pain that can occur as aresult of disk herniation can be very intense and may thus affect theindividual patient's whole life situation during the sickness period.

U.S. Pat. No. 5,703,092 discloses the use of dydroxamic acid compoundsand carbocyclic acids as metalloproteinase and TNF inhibitors, and inparticular in treatment of arthritis and other related inflammatorydiseases. No use of these compounds for the treatment of nerve rootinjuries is disclosed or hinted at.

U.S. Pat. No. 4,925,833 discloses the use of tetracyclines to enhancebone protein syntheses, and treatment of osteoporosis.

U.S. Pat. No. 4,666,897 discloses inhibition of mammalian collagenolyticenzymes by tetracyclines. The collagenolytic activity is manifested byexcessive bone resorption, periodontal disease, rheumatoid arhritis,ulceration of cornea, or resorption of skin or other connective tissuecollagen.

Neither of these latter two documents mentions nerve root injury or thetreatment thereof.

DESCRIPTION OF THE PRESENT INVENTION

It has now surprisingly been shown possible to be able to treat nerveroot injuries, or at least alleviate the symptoms of nerve root injuriesby using a pharmaceutical composition comprising an therapeuticallyactive amount of a TNF-α inhibitor selected from the group consisting ofmetalloproteinase inhibitors excluding methylprenisolone, tetracyclinesincluding chemically modified tetracyclines, quinolones,corticosteroids, thalidomide, lazaroides, pentoxyphylline, hydroxamicacid derivatives, napthopyrans, soluble cytokine receptors, monoclonalantibodies towards TNF-α, amrinone, pimobendan, vesnarinone,phosphodiesterase III inhibitors, lactoferrin and lactoferrin derivedanalogous, and melatonin in the form of bases or addition salts togetherwith a pharmaceutically acceptable carrier.

The therapeutically effective amount is a dosage normally used whenusing such compounds for other therapeutic uses. Many of these drugs arecommercially known registered drugs.

Compounds that possess this activity are tetracyclines, such-astetracycline, doxycycline, lymecycline, oxytetracycline, minocycline,and chemically modified tetracyclines dedimethylaminotetracycline,hydroxamic acid compounds, carbocyclic acids and derivatives,thalidomide, lazaroides, pentoxyphylline, napthopyrans, soluble cytokinereceptors, monoclonal antibodies towards TNF-α, amrinone, pimobendan,vesnarinone, phosphodiesterase III inhibitors, lactoferrin andlactoferrin derived analogous, melatonin, norfloxacine, ofloxacine,ciprofloxacine, gatifloxacine, pefloxacine, lomefloxacine, andtemafioxacine. These can be present as bases or in the form of additionsalts, whichever possesses the best pharmaceutical effect, and bestproperty to be brought into a pharmaceutical suitable composition.

Further, the active component comprises a substance inhibiting acompound trigged by the release of TNF-α, such as interferon-gamma,interleukin-1, and nitrogen oxide (NO) in the form of base or additionsalts.

The invention further relates to a method for inhibiting the symptoms ofnerve root injury.

The effects of doxycycline, soluble cytokine-receptors, and monoclonalcytokine-antibodies have been studied and the methods used and resultsobtained are disclosed below.

EXAMPLE

Study Design

The effects of nucleus pulposus and various treatments to block TNF-αactivity were evaluated in an experimental set-up usingimmnunohistochemistry and nerve conduction velocity recordings.

Summary of Background Data

A meta-analysis of observed effects induced by nucleus pulposus revealsthat these effects might relate to one specific cytokine, Tumor NecrosisFactor alpha (TNF(α).

Objectives

To assess the presence of TNF(α) in pig nucleus pulposus cells and tosee if blockage of TNF(α) also blocks the nucleus pulposus-inducedreduction of nerve root conduction velocity.

Methods

Series-1: Cultured nucleus pulposus-cells were immunohistologicallystained with a monoclonal antibody for TNF(α).

Series-2: Nucleus pulposus was harvested from lumbar discs and appliedto the sacro-coccygeal cauda equina in 13 pigs autologously. Four pigsreceived 100 mg of doxycycline intravenously, 5 pigs had a blockingmonoclonal antibody to TNF-α applied locally in the nucleus pulposus,and 4 pigs remained non-treated and formed control. Three days after theapplication the nerve root conduction velocity was determined over theapplication zone by local electrical stimulation.

Series-3: Thirteen pigs had autologous nucleus pulposus placed ontotheir sacrococcygeal cauda equina similar to series-2. Five pigs(bodyweight 25 kg) received REMICADE® (infliximab) 100 mg i.v.preoperatively, and 8 pigs received ENBREL® (etanercept) 12.5 mg s.c.preoperatively and additionally 12.5 mg s.c. three days after theoperation. Seven days after the nucleus pulposus-application the nerveroot conduction velocity was determined over the application zone bylocal electrical stimulation according to series-2.

Results

Series-1: TNF-α was found to be present in the nucleus pulposus-cells.Series-2: The selective antibody to TNF-α limited the reduction of nerveconduction velocity, although not statistically significantly to thecontrol series. However, treatment with doxycycline significantlyblocked the nucleus pulposus-induced reduction of conduction velocity.

Series-3: Both drugs (infliximab, and etanercept) blocked the nucleuspulposus induced nerve injury efficiently and normal average nerveconduction velocities were found after treatment with both of these twodrugs.

Conclusion

For the first time a specific substance, Tumor Necrosis Factor-alpha,has been linked to the nucleus pulposus-induced effects of nerve rootsafter local application. Although the effects of this substance may besynergistic with other similar substances, the data of the present studymay be of significant importance for the continued understanding ofnucleus pulposus' biologic activity, and might also be of potential usefor future treatment strategies of sciatica.

After previously being considered as just a biologically inactive tissuecomponent compressing the spinal nerve root at disc herniation, thenucleus pulposus has recently been found to be highly active, inducingboth structural and functional changes in adjacent nerve roots whenapplied epidurally (24, 37, 38, 41, 42). It has thereby been establishedthat autologous nucleus pulposus may induce axonal changes and acharacteristic myelin injury (24, 38, 41, 42), increased vascularpermeability (9, 44), intra vascular coagulation (24, 36), and thatmembrane-bound structure or substances of the nucleus pulposus-cells areresponsible for these effects (24, 37). The effects have also been foundto be efficiently blocked by methyl-prednisolone and cyclosporin A (2,38). When critically looking at these data, one realizes that there isat least one cytokine that relates to all of these effects, TumorNecrosis Factor alpha (TNF-α). To assess if TNF-α may be involved in thenucleus pulposus induced nerve root injury the presence of TNF-α innucleus pulposus-cells was assessed and was studied if the nucleuspulposus-induced effects could be blocked by doxycycline, a solubleTNF-receptor, and a selective monoclonal TNF-antibody, the latteradministered both locally in the nucleus pulposus and systemically.

MATERIAL AND METHODS

Series-1, Presence of TNF-α in pig nucleus pulposus-cells:

Nucleus pulposus (NP) from a total of 13 lumbar and thoracic discs wereobtained from a pig used for other purposes. NP was washed once in Ham'sF12 medium (Gibco BRL, Paisley, Scotland) and then centrifuged andsuspended in 5 ml of collagenase solution in Ham's F12 medium (0.8mg/ml, Sigma Chemical Co., St Louis, Mo., USA) for 40 minutes, at 37° C.in 25 cm² tissue culture flasks. The separated NP-cell pellets weresuspended in DMEM/F12 1:1 medium (Gibco BRL, Paisley, Scotland)supplemented with 1% L-glutamine 200 mM (Gibco BRL, Paisley, Scotland),50 μg/ml gentamycine sulphate (Gibco BRL, Paisley, Scotland) and 10%foetal calf serum (FCS), (Gibco BRL, Paisley, Scotland). The cells werecultured at 37° C. and 5% CO₂ in air for 3-4 weeks and then cultureddirectly on tissue culture treated glass slides (Becton Dickinson & CoLabware, Franklin Lakes, N.J., USA). After 5 days on the glass slides,the cells were fixed in situ by acetone for 10 minutes. After blockingirrelevant antigens by application of 3% H₂0₂ (Sigma Chemical Co., StLouis, Mo, USA) for 30 minutes and Horse Serum (IrnmunoPure ABC,peroxidase mouse IgG staining kit nr.32028, Pierce, Rockford, Ill.) for20 minutes, the primary antibody (Anti-pig TNF-α monoclonal purifiedantibody, Endogen, Cambridge, Mass., USA) was applied over night at +40°C., diluted at 1:10, 1:20 and 1:40. For control, BSA (bovine serumalbumin, Intergen Co, New York, USA) suspended in PBS (phosphatebuffered saline, Merck, Darmstadt, Germany) was applied in the samefashion. The next day the cells were washed with 1% BSA in PBS and thesecondary antibody ((ImmunoPure ABC, peroxidase mouse IgG staining kitnr.32028, Pierce, Rockford, Ill.) was applied for 30 minutes. To enhancethis reaction, the cells were exposed to Avidin-Biotin complex foradditionally 30 minutes (ImmunoPure ABC, peroxidase mouse IgG stainingkit nr.32028, Pierce, Rockford, Ill.). The cells were then exposed to 20mg of DAB (3,3-diarninobenzidine tetrahydrochloride nr. D-5905, SigmaChemical Co., St Louis, Mo., USA) and 0.033 ml of 3% H₂O₂ in 10 ml ofsaline for 10 minutes. The cells were washed in PBS, dehydrated in aseries of ethanol, mounted and examined by light microscopy by anunbiased observer regarding the presence of a brown colourationindicating presence of TNF-α.

Series-2, Neurophysiologic evaluation

Thirteen pigs, (body weight 25-30 kg) received an intramuscularinjection of 20 mg/kg body weight of KETALAR® (ketamine 50 mg/ml,Parke-Davis, Morris Plains, N.J.) and an intravenous injection of 4mg/kg body weight of Hypnodil® (methomidate chloride 50 mg/ml, AB Leo,Helsingborg, Sweden) and 0.1 mg/kg body weight of STRESNIL® (azaperon 2mg/ml, Janssen Pharmaceutica, Beerse, Belgium). Anaesthesia wasmaintained by additional intravenous injections of 2 mg/kg body weightof HYPNODIL® and 0.05 mg/kg body weight of STRESNIL®. The pigs alsoreceived an intravenous injection of 0.1 mg/kg of STESOLID® NOVUM®(Diazepam, Dumex, Helsingborg, Sweden) after surgery.

Nucleus pulposus was harvested from the 5th lumbar disc through a retroperitoneal approach (42). Approximately 40 mg of the nucleus pulposuswas applied to the sacrococcygeal cauda equina through a midlineincision and laminectomy of the first coccygeal vertebra. Four pigs didnot receive any treatment (no treatment). Four other pigs received anintravenous infusion of 100 mg of doxycycline (Vibramycino, Pfizer Inc.,N.Y., USA) in 100 ml of saline over 1 hour. In 5 pigs, the nucleuspulposus was mixed with 100 gl of a 1,11 mg/ml suspension of theanti-TNF-α antibody used in series 1, before application.

Three days after the application, the pigs were reanaesthetized by anintramuscular injection of 20 mg/kg body weight of KETALAR® and anintravenous injection of 35 mg/kg body weight of PENTOTHAL® (Thiopentalsodium, Abbott lab, Chicago, Ill.). The pigs were ventilated on arespirator. Anaesthesia was maintained by an intravenous bolus injectionof 100 mg/kg body weight of Chloralose (α)-D(+)-gluco-chloralose, Merck,Darmstadt, Germany) and by a continuous supply of 30 mg/kg/hour ofChloralose. A laminectomy from the 4th sacral to the 3rd coccygealvertebra was performed. The nerve roots were covered with SPONGOSTANE®(Ferrosan, Demnark). Local tissue temperature was continuously monitoredand maintained at 37.5-38.0° C. by means of a heating lamp.

The cauda equina was stimulated by two E2 subdermal platinum needleelectrodes (Grass Instrument Co., Quincy, Mass.) which were connected toa Grass SD9 stimulator (Grass Instrument Co., Quincy, Mass.) and gentlyplaced intermittently on the cauda equina first 10 mm cranial and then10 mm caudal to the exposed area To ensure that only impulses fromexposed nerve fibres were registered, the nerve root that exited fromthe spinal canal between the two stimulation sites were cut. An EMG wasregistered by two subdermal platinum needle electrodes which were placedinto the paraspinal muscles in the tail approximately 10 mm apart. Thisprocedure is reproducible and represents a functional measurement of themotor nerve fibres of the cauda equina nerve roots. The EMG wasvisualized using a Macintosh IIci computer provided with Superscopesoftware and MacAdios II AID converter (GW Instruments, Sommerville,Mass.) together with a Grass P18 preamplifier (Grass Instrument Co.,Quincy, Mass.). The separation distance between the first peaks of theEMG from the two recordings was determined and the separation distancebetween the two stimulation sites on the cauda equina was measured withcalipers. The nerve conduction velocity between the two stimulationsites could thus be calculated from these two measurements.

The person performing the neurophysiologic analyses was unaware of theexperimental protocol for the individual animal, and after finishing thecomplete study the data were arranged in the three experimental groupsand statistical differences between the groups were assessed byStudent's t-test. The experimental protocol for this experiment wasapproved by the local animal research ethics committee.

Series-3: Thirteen pigs had autologous nucleus pulposus placed ontotheir sacrococcygeal cauda equina similar to series-2. Five pigs(bodyweight 25 kg) received the human/murine monoclonal antibodyREMICADE® (infliximab, Immunex Corporation, Seattle, Wash. 98101, USA)100 mg i.v. preoperatively, and 8 pigs received ENBREL® (etanercept,Centocor B.V., Leiden, the Netherlands) 12.5 mg s.c. preoperatively andadditionally 12.5 mg s.c. three days after the operation. Seven daysafter the nucleus pulposus-application the nerve root conductionvelocity was determined over the application zone by local electricalstimulation according to series-2. To blind the study theneurophysiological evaluation was conducted in parallel to another studyand the person performing the analyses did not know from which study andwhat treatment each specific animal was subjected to. No non-treatedanimals were included in the series-3 due to the pre-existing knowledgeof nerve conduction velocity after seven days of either nucleus pulposusor fat (control) application. The statistical difference between thegroups, infliximab, and etanercept, nucleus pulposus without treatment(positive control from previous data) and application of retroperitonealfat (negative control from previous data) was assessed by using ANOVAand Fisher's PLSD at 5%.

RESULTS

Series-1, Presence of TNF-A in pig nucleus pulposus-cells:

Examples of the light microscopic appearance of the stained glassslides. In the sections using BSA in PBS as “primary antibody” (control)no staining was observed, ensuring that there was no labelling andvisualization of irrelevant antigens. When the anti-TNF-α antibody wasapplied at 1:40 dilution there was only a weak staining. However, thestaining increased with diminishing dilutions of the antibody. Thestaining was seen in the soma of the cells and it was not possible todifferentiate whether TNF-α was located in the cytoplasm, on the cellsurface bound to the cell-membrane, or both.

Series-2, Neurophysiologic evaluation:

Application of non-modified nucleus pulposus and without any treatmentinduced a reduction in nerve conduction velocity similar to previousstudies (Table 1), whereas treatment with doxycycline completely blockedthis reduction (p<0.0l Student's t-test). Local application ofanti-TNF-α-antibody also induced a partial block of this reduction,although not as complete as doxycycline and not statisticallysignificant to the no treatment-series.

Series-3: Treatment with both drugs seemed to prevent the nucleuspulposus-induced reduction of nerve root conduction velocities since theaverage nerve conduction velocity for both these treatment groups wereclose to the average conduction of fat-application series as seen in aprevious study (Table 2). There was a statistically significantdifference to application of nucleus pulposus, but without anytreatment, seen for both drugs.

TABLE 1 Series-2 Treatment n NCV(m/s + SD) Local anti-TNF-α 5 64 ± 28Doxycycline 4 76 ± 9  No treatment 4 46 ± 12

TABLE 2 Series-3 Treatment n NCV(m/s + SD) Fat* 5 76 ± 11 EMBREL ® 8 78± 14 REMICADE ® 5 79 ± 15 No treatment* 5 45 ± 19 *Data included fromref. no. 42, Olmarker et al, 1993

DISCUSSION

The data of the present study demonstrated that TNF-α may be found innucleus pulposus-cells of the pig. If TNF-α was blocked by a locallyapplied selective monoclonal antibody, the nucleus pulposus-inducedreduction of nerve root conduction velocity was partially blocked,although not statistically significant compared to the series withnon-treated animals. However, if systemic treatments with doxycycline,infliximab, and etanercept were used to inhibit TNF-α, the reduction ofnerve conduction velocity was significantly prevented.

In recent years, it has been verified that local application ofautologous nucleus pulposus may injure the adjacent nerve roots. Thus,it has become evident that the nerve root injury seen as disc herniationmay not be solely based on mechanical deformation of the nerve root, butmay also be induced by unknown “biochemical effects” related to theepidural presence of herniated nucleus pulposus. Although this newresearch field has generated many experimental studies, the mechanismsand substances involved are not fully known. It has been seen that localapplication of autologous nucleus pulposus may induce axonal injury (24,37, 38, 40-42), a characteristic injury of the myelin sheath (24, 38,40-42), a local increase of vascular permeability (9, 36, 44), intravascular coagulations, reduction of intra neural blood flow (43), andleukotaxis (36). It has been seen that the nucleus pulposus-relatedeffects may be blocked efficiently by methylprednisolone (38) andcyclosporin A (2), and slightly less efficiently by indomethacin (3),and lidocaine (69). Further, it has been understood that the effects aremediated by the nucleus pulposus-cells (37), particularly by substancesor structures bound to the cell-membranes (25). When criticallyconsidering these data, it becomes evident that at least one specificcytokine could be related to these observed effects, Tumor NecrosisFactor-alpha (TNF-α). TNF-α may induce nerve injury (29, 31, 45, 50, 66)mainly seen as a characteristic myelin injury that closely resembles thenucleus pulposus-induced myelin-injury (29, 47, 51, 54, 62, 64, 66, 70).TNF-α may also induce an increase in vascular permeability (47, 66) andinitiate coagulation (22, 34, 63). Further, TNF-α may be blocked bysteroids (4, 8, 21, 61, 68), and cyclosporin A (11, 55, 67, 68).However, the blocking effect on TNF-α is not so pronounced by NSAID (14,17, 20) and very low or the opposite by lidocaine (5, 32, 46, 60). Itwas recently observed that local application of nucleus pulposus mayinduce pain-related behaviour in rats, particularly thermal hyperalgesia(23, 40). TNF-α has also been found to be related to suchpain-behaviouristic changes (12, 35, 56, 66), and also to neuropathiesin general (30, 54, 56, 57). However there are no studies that haveassessed the possible presence of TNF-α in the cells of the nucleuspulposus.

To assess if TNF-α could be related to the observed nucleus pulposusinduced reduction in nerve root conduction velocity it was necessaryfirst to analyse if there was TNF-α in the nucleus pulposus-cells. Thedata clearly demonstrated that TNF-α was present in these cells. TNF-αis produced as precursor pro-TNF) that is bound to the membrane and itis activated by cleavage from the cell-membrane by a zinc-dependentmetallo-endopeptidase (TNF-α converting enzyme, TACE) (6, 15, 16, 48,49). This may thus relate well to experimental findings whereapplication of the mere cell-membranes of autologous nucleuspulposus-cells induced nerve conduction velocity reduction, whichindicated that the effects were mediated by a membrane-bound substances.Second, the effects of the TNF-α had to be blocked in a controlledmanner. We then first chose to add the sarne selective antibody that wasused for immunohistochemistry in series 1, which is known to also blockthe effects of TNF-α, to the nucleus pulposus before application. Also,we chose to treat the pigs with doxycycline, which is known to blockTNF-α (26, 27, 33, 52, 53). However, due to the low pH of thedoxycycline preparation it was chosen to treat the pigs by intravenousinjection instead of local addition to the nucleus pulposus sincenucleus pulposus at a low pH has been found to potentiate the effects ofthe nucleus pulposus (38, 39).

Two recently developed drugs for specific TNF-a inhibition were alsoincluded in the study. Infliximab is a chimeric monoclonal antibodycomposed of human constant and murine variable regions, and bindsspecifically to human TNF-α. As opposed to the monoclonal antibody usedin series-2 for the 3 days observation period, inflixirnab was notadministered locally in the autotransplanted nucleus pulposus butinstead systemically in a clinically recommended dose (4 mg/kg).Etanercept is a dimeric fusion protein consisting of the Fc portion ofhuman IgG. The drug was administered in a dosage comparable to therecommended dose for pediatric use (0.5 mg/kg, twice a week).

The data regarding nerve conduction velocity showed that the reductionwas completely blocked by the systemic-treatment and that the nerveconduction velocities in these series were close to the conductionvelocity after application of a control substance (retro peritoneal fat)from a previous study (42). Application of the anti-TNF-α-antibody tothe nucleus pulposus also partially prevented the reduction in nerveconduction velocity, however, not as pronounced as doxycycline, and thevelocity in this series was not statistically different to the velocityin the series with not treated animals, due to the wide deviation of thedata.

The fact that the local anti-TNF-α antibody treatment only partiallyblocked the nucleus pulposus-induced reduction of nerve conductionvelocity and the high standard deviation of the data could probably haveat least three different explanations. First, if looking at the specificdata within this group it was found that the nerve conduction velocitywas low in 2 animals (mean 37.5 m/s) and high in 3 animals (mean 81.3m/s). There are thus 2 groups of distinctly different data within theanti-TNF-α treatment series. This will account for the high standarddeviation and might imply that the blocking effect was sufficient in 3animals and non-sufficient in 2 animals. The lack of effects in theseanimals could be based simply on the amount of antibodies in relation toTNF-α molecules not being sufficient, and if a higher dose of theantibody had been used, the TNF-α effects would thus have been blockedeven in these animals. Such a scenario could then theoretically implythat TNF-α alone is responsible for the observed nucleuspulposus-induced effects, and that this could not be verifiedexperimentally due to the amount of antibody being too low.

Second, it is also known that tetracyclines such as doxycycline andminocycline may block a number of cytokines and other substances. Forinstance they may block IL-1 (1,28,58), IFNγ (27), NO-synthetasel, andmetalloproteinases (1, 53, 58). Particularly IL-1 and IFNγ are known toact synergistically with TNF-α and are known to be more or lessneurotoxic (7, 10, 13, 18, 19, 56, 59). These substances are alsoblocked by steroids and cyclosporin A which corresponds well with theprevious observations on nucleus pulposus-induced nerve root injurywhich have shown that the nucleus pulposus-induced effects may beblocked by these substances (8, 67). One may therefore also consider thepossibility that a selective block of TNF-α may not be sufficient tocompletely block the nucleus pulposus-induced effects on nerve function,and that simultaneous block of other synergistic substances is necessaryas well. Thus, this scenario, on the other hand, implies that TNF-α isnot solely responsible for the nucleus pulposus-induced effects, andthat other synergistic substances, which are also blocked bydoxycycline, may be necessary.

The third explanation could be that the amount of TNF in the nucleuspulposus may well be enough to start the pathophysiologic cascadelocally in the nerve root, comprising increased vascular permeabilityand aggregation and recruitment of systemic leukocytes. However, it isthese leukocytes that have the major content of TNF-α and that systemictreatment in a sufficient dose is necessary to block the contributionfrom these leukocytes, and thereby also blocking the events leading tonerve injury.

TNF-α may have various pathophysiologic effects. It may have directeffects on tissues such as nerve tissue and blood vessels, it maytrigger other cells to produce other pathogenic substances and it maytrigger release of more TNF-α both by inflammatory cells and also bySchwann-cells locally in the nerve tissue (65). There is thus reason tobelieve that even low amounts of TNF-α may be sufficient to initiatethese processes and that there is a local recruitment of cytokineproducing cells and a subsequent increase in production and release ofother cytokines as well as TNF-α. TNF-α may therefore act as the“ignition key” of the pathophysiologic processes and play an importantrole for the initiation of the pathophysiologic cascade behind thenucleus pulposus-induced nerve injury. However, the major contributionof TNF-α may be derived from recruited, aggregated and maybe evenextravasated leukocytes, and that successful pharmacologic block may beachieved only by systemic treatment.

In conclusion, although the exact role of TNF-α can not be fullyunderstood from the experimental set-up, we may conclude that for thefirst time a specific substance (TNF-α) has been linked to the nucleuspulposus-induced nerve root injury. This new information may be ofsignificant importance for the continued understanding of nucleuspulposus-induced nerve injury as well as raising the question of thepotential future clinical use of pharmacological interference with TNF-αand related substances, for treatment of sciatica.

The presence of TNF-α in pig nucleus pulposus-cells was thusimmununohistochemically verified. Block of TNF-α by a locally appliedmonoclonal antibody partially limited the nucleus pulposus-inducedreduction of nerve root conduction velocity, whereas intravenoustreatment with doxycycline, infliximab, and etanercept significantlyblocked this reduction. These data for the first time links one specificsubstance, TNF-α, to the nucleus pulposus-induced nerve injury.

Aminoguanidine has showed to inhibit the release of nitrogen oxide (NO)at nerve root injuries by inhibiting inducible nitrogen oxidesynthetase, and aminoguanidine is thus one compound that inhibits acompound trigged by the release of TNF-α.

The compounds of the invention can be administered in a variety ofdosage forms, e.g, orally, in the form of tablets, capsules, sugar orfilm coated tablets, liquid solutions; rectally, in the form ofsuppositories; parenterally, e.g., intramuscularly or by intravenousinjection or infusion. The therapeutic regimen for the differentclinical syndromes must be adapted to the type of pathology taken in toaccount, as usual, also the route of administration, the form in whichthe compound is administered and age, weight, and condition of thesubject involved.

The oral route is employed, in general, for all conditions, requiringsuch compounds. In emergency cases preference is given to intravenousinjection. For these purposes the compounds of the invention can beadministered orally at doses ranging from about 20 to about 1500 mg/day.Of course, these dosage regimens may be adjusted to provide the optimaltherapeutic response.

The nature of the pharmaceutical composition containing the compounds ofthe invention in association with pharmaceutically acceptable carriersor diluents will, of course, depend upon the desired route ofadministration. The composition may be formulated in the conventionalmanner with the usual ingredients. For example, the compounds of theinvention may be administered in the form of aqueous or oily solutionsor suspensions, tablets, pills, gelatine capsules (hard or softones)syrups, drops or suppositories.

Thus for oral administration, the pharmaceutical compositions containingthe compounds of the invention are preferably tablets, pills or gelatinecapsules, which contain the active substance together with diluents,such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose;lubricants, e.g., silica, talc, stearic acid, magnesium or calciumstearate, and/or polyethylene glycols; or they may also contain binders,such as starches, gelatine, methyl cellulose, carboxymethylcellulose,gum arabic, tragacanth, polyvinylpyrrolidone; disaggregating agents suchas starches, alginic acid, alginates, sodium starch glycolate,microcrystalline cellulose; effervescing agents such a carbonates andacids; dyestoffs; sweeteners; wetting agents, such as lecithin,polysorbates, laurylsulphates; and in general non-toxic andpharmaceutically inert substances used in the formulation ofpharmaceutical compositions. Said pharmaceutical compositions may bemanufactured in known manners, e.g., by means of mixing, granulating,tableting, sugar-coating or film-coating processes. In the case filmproviding compounds can be selected to provide release in the rightplace in the intestinal tract with regard to absorption and maximumeffect. Thus pH-dependent film formers can be used to allow absorptionin the intestines as such, whereby different phthalate are normally usedor acrylic acid/methacrylic acid derivatives and polymers.

The liquid dispersions for oral administration may be e.g., syrups,emulsion, and suspensions.

The syrups may contain as carrier, e.g., saccharose, or saccharose withglycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, e.g., a natural gum,such as gum arabic, xanthan gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, polyvinyl alcohol.

The suspension or solutions for intramuscular injections may containtogether with the active compound, a pharmaceutically acceptablecarrier, such as e.g., sterile water, olive oil, ethyl oleate, glycols,,e.g., propylene glycol, and if so desired, a suitable amount oflidocaine hydrochloride. Adjuvants for trigging the injection effect canbe added as well.

The solutions for intravenous injection or infusion may contain ascarrier, e.g., sterile water, or preferably, a sterile isotonic salinesolution, as well as adjuvants used in the field of injection of activecompounds.

The suppositories may contain together with the active compound, apharmaceutically acceptable carrier, e.g., cocoa-butter polyethyleneglycol, a polyethylene sorbitan fatty acid ester surfactant or lecithin.

REFERENCES

1. Amin A R, Attur M G, Thakker G D, Patel P D, Vyas P R, Patel R N,Patel I R, Abramson S B. A novel mechanism of action of tetracyclines:effects on nitric oxide syntheses. Proc Natl Acad Sci U S A 1996;93:14014-9.

2. Arai I, Konno S, Otani K, Kikuchi S, Olmarker K. Cyclosporin A blocksthe toxic effects of nucleus pulposus on spinal nerve roots. Manuscript

3. Arai I, Mao GP, Otani K, Konno S, Kikuchi S, Olmarker K. Indomethacinblocks nucleus pulposus related effects in adjacent nerve roots.Manuscript

4. Baumgartner R A, Deramo V A, Beaven M A. Constitutive and induciblemechanisms for synthesis and release of cytokines in immune cell lines.J Immunol 1996;157:4087-93.

5. Bidani A, Heming T A. Effects of lidocaine on cytosolic pH regulationand stimulus-induced effector functions in alveolar macrophages. Lung1997;175:349-61.

6. Black R A, Rauch C T, Kozlosky C J, Peschon J J, Slack J L, Wolfson MF, Castner B J, Stocking K L, Reddy P, Srinivasan S, Nelson N, Boiani N,Schooley K A, Gerhart M, Davis R, Fitzner J N, Johnson R S, Paxton R J,March C J, Cerretti D P. A metalloproteinase disintegrin that releasestumour-necrosis factor-α from cells. Nature 1997;385:729-33.

7. Bluthe R M, Dantzer R, Kelley K W. Interleukin-1 mediates behaviouralbut not metabolic effects of tumor necrosis factor alpha in mice. Eur JPhannacol 1991;209:281-3.

8. Brattsand R, Linden M. Cytokine modulation by glucocorticoids:mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10:81-90.

9. Byrod G, Otani K, Rydevik B, Olmarker K. Acute increase in endoneuralvascular permeability induce by epidural application of nucleus pulposuson spinal nerve roots. Manuscript

10. Chao C C, Hu S, Ehrlich L, Peterson P K. Interleukin-1 and tumornecrosis factor-alpha synergistically mediate neurotoxicity: involvementof nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun1995;9:355-65.

11. Dawson J, Hurtenbach U, MacKenzie A. Cyclosporin A inhibits the invivo production of interleukin-Ibeta and tumour necrosis factor alpha,but not interleukin-6, by a T-cell-independent mechanism. Cytokine1996;8:882-8.

12. DeLeo J A, Colburn R W, Rickman A J. Cytokine and growth factorimmunohistochemical spinal profiles in two animal models ofmononeuropathy. Brain Res 1997;759:50-7.

13. Gadient R A, Cron K C, Otten U. Interleukin-1 beta and tumornecrosis factor-alpha synergistically stimulate nerve growth factor(NGF) release from cultured rat astrocytes. Neurosci Lett1990;117:335-40.

14. Garcia-Vicuna R, Diaz-Gonzalez F, Gonzalez-Alvaro 1, del Pozo MA,Moilinedo F, Cabanas C, Gonzalez-Amaro R, Sanchez-Madrid F. Preventionof cytokine-induced changes in leucocyte adhesion receptors bynonsteroidal antiinflammatory drugs from the oxicam family. ArthritisRheum 1997;40:143-53.

15. Gearing A J, Beckett P, Christodoulou M, Churchill M, Clements J,Davidson A H, Drummond A H, Galloway W A, Gilbert R, Gordon J L, et al.Processing of tumour necrosis factor-alpha precursor bymetalloproteinases. Nature 1994;370:555-7.

16. Gazelle E J, Banda M J, Leppert D. Matrix metallo-proteinases inimmunity. J Immunol 1996; 156: 14.

17. Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero-Beaumont G.Long-term effect of nonsteroidal anti-inflammatory drugs on theproduction of cytokines and other inflammatory mediators by blood cellsof patients with osteosis. Agents Actions 1994;41:171-8.

18. Hartung H P, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos J J,Toyka K V. Inflammatory mediators in demyelinating disorders of the CNSand PNS. J Neuroinununol 1992;40:197-210.

19. Hattori A, Iwasald S, Murase K, Tsujimoto M, Sato M, Hayashi K,Kohno M. Tumor necrosis factor is markedly synergistic with interleukinI and ii3terferon-gamma in stimulating the production of nerve growthfactor in fibroblasts. FEBS Lett 1994;340:177-80.

20. Herman J H, Sowder W G, Hess E V. Nonsteroidal antiinflammatory drugmodulation of prosthesis pseudomembrane induced bone resorption. JRheunutol 1994;21 :338-43.

21. Iwamoto S, Takeda K. [Possible cytotoxic mechanisms of TNF invitro]. Hum Cell 1990;3:107-12.

22. Jurd K M, Stephens C J, Black M M, Hunt B J. Endothelial cellactivation in cutaneous vasculitis. Clin Exp Dermatol 1996;21:28-32.

23. Kawakami M, Tamaki T, Weinstein J N, Hashizume H, Nishi H, Meller ST. Pathomechanism of pain-related behaviour produced by allografts ofintervertebral disc in the rat. Spine 1996;21:2101-7.

24. Kayama S, Konno S, Olmarker K, Yabuki S, Kikuchi S. Incision of theanulus fibrosis induces nerve root morphologic, vascular, and functionalchanges. An experimental study. Spine 1996;21:2539-43.

25. Kayama S, Olmarker K, Larsson K, Sjögren-Jansson E, Lindahl A,Rydevik B. Cultured, autologous nucleus pulposus cells induce structuraland functional changes in spinal nerve roots. Spine, 1998,23:90:2155-58,

26. Kloppenburg M, B˜an B M, de Rooij-Dijk H H, Miltenburg A M, Daha MR, Breedveld F C, Dijkmans B A, Verweij C. The tetracycline derivativeminocycline differentially affects cytokine production by monocytes andT lymphocytes. Antimicrob Agents Chemother 1996;40:934-40.

27. Kloppenburg M, Verweij C L, Miltenburg A M, Verboeven A J, Daha M R,Dijkmans B A, Breeveld F C. The influence of tetracyclines on T cellactivation. Clin Exp Immunol 1995;102:635-41.

28. Lamster I B, Pullman J R, Celenti R S, Grbic J T. The effect oftetracycline fiber therapy on beta-glucuronidase and interleukin-1 betain crevicular fluid. J Clin Periodontol 1996;23:816-22.

29. Liberski P P, Yanagihara R, Nerurkar V, Gajdusek D C. Furtherultrastructural studies of lesions induced in the optic nerve by tumornecrosis factor alpha (TNF-α): a comparison with experimentalCreutzfeldt-Jakob disease. Acta Neurobiol Exp (Warsz) 1994;54:209-18.

30. Lin X H, Kashima Y, Khan M, Heller K B, Gu X Z, Sadun A A. Animmunohistochemical study of TNF-α in optic nerves from AIDS patients.Curr Eve Res 1997;16:1064-8.

31. Madigan M C, Sadun A A, Rao N S, Dugel P U, Tenhula W N, Gill P S.Tumor necrosis factor-alpha (TNF-α)-induced optic neuropathy in rabbits.Neurol Res 1996; 18:176-84.

32. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodaroneinhibits production of tumor necrosis factor-alpha by human mononuclearcells: a possible mechanism for its effect in heart failure. Circulation1997;96:1386-9.

33. Milano S, Arcoleo F, D'Agostino P, Cillari E. Intraperitonealinjection of tetracyclines protects mice from lethal endotoxemiadownregulating inducible nitric oxide synthase in various organs andcytokine and nitrate secretion in blood. Antimicrob Agents Chemother1997;41:117-21.

34. Nawroth P, Handley D, Matsueda G, De Waal R, Gerlach H, Blohin D,Stem D. Tumor necrosis factor/cachectin-induced intra vascular fibrinformation in meth A fibrosarcomas. J Exp Med 1988;168:637-47.

35. Oka T, Wakugawa Y, Hosoi M, Oka K, Hori T. Intracerebroventricularinjection of tumor necrosis factor-alpha induces thermal hyperalgesia inrats. Neuroimmunomodulation 1996;3: 135-40.

36. Olmarker K, Blomquist J, Stromberg J, Nannmark, U, Thomsen P,Rydevik B. Inflamma-togenic properties of nucleus pulposus. Spine1995;20:665-9.

37. Olmarker K, Brisby H, Yabuki S, Nordborg C, Rydevik B. The effectsof normal, frozen, and hyaluronidase-digested nucleus pulposus on nerveroot structure and function. Spine 1997;22:4715; discussion 476.

38. Olmarker K, Byrod G, Comefjord M, Nordborg C, Rydevik B. Effects ofmethylprednisolone on nucleus pulposus-induced nerve root injury. Spine1994; 19:1803-8.

39. Olmarker K, lwabuchi M, Larsson K, Rydevik B. Effects of in vitrodegenerated nucleus pulposus on nerve root conduction velocity.Manuscript

40. Olmarker K, Myers R R. Pathogenesis of sciatic pain: Role ofherniated nucleus pulposus and deformation of spinal nerve root and DRG.Pain, 1998, 78:9-105

41. Olmarker K, Nordborg C, Larsson K, Rydevik B. Ultrastructuralchanges in spinal nerve roots induced by autologous nucleus pulposus.Spine 1996;21:411-4.

42. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposusinduces neurophysiologic and histologic changes in porcine cauda equinanerve roots [see comments]. Spine 1993;18:1425-32.

43. Otani K, Arai I, Mao G P, Konno S, Olmarker K, Kikuchi S. Nucleuspulposus-induced nerve root injury. The relationship between blood flowand nerve conduction velocity. Manuscript

44. Otani K, Mao G P, Arai I, Konno S, Olmarker K, Kikuchi S. Nucleuspulposus-induced increase in vascular permeability in the nerve root.Manuscript

45. Petrovich M S, Hsu H Y, Gu X, Dugal P, Heller K B, Sadun A A.Pentoxifylline suppression of TNF- alpha mediated axonal degeneration inthe rabbit optic nerve. Neurol Res 1997; 19:551-4.

46. Pichler W J, Zanni M, von Greyerz S, Schnyder B, Mauri-HeUweg D,Wendland, T. High IL-5

production by human drug-specific T cell clones. Int Arch Allerg Immunol1997; 1 13 :177-80.

47. Redford E J, Hall S M, Smith K J. Vascular changes and demyelinationinduced by the intra neural injection of tumour necrosis factor. Brain1995; 1 18 :869-78.

48. Robache-Gallea S, Bruneau J M, Robbe H, Morand V, Capdevila C,Bhatnagar N, Chouaib S, Roman-Roman S. Partial purification andcharacterization of a tumor necrosis factor- alpha converting activity.Eur J Immunol 1997;27:1275-82.

49. Rosendahl M S, Ko S C, Long D L, Brewer M T, Rosenzweig B, Hedl E,Anderson L, Pyle S M, Moreland J, Meyers M A, Kohno T, Lyons D,Lichenstein H S. Identification and characterization of a pro-tumornecrosis factor- alpha-processing enzyme from the ADAM family of zincmetalloproteases. J Biol Chem 1997;272:24588-93.

50. Said G, Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophageactivation. Res Immunol 1992;143:589-99.

51. Sehnaj K W, Raine C S. Tumor necrosis factor mediates myelin andoligodendrocyte damage in vitro. Ann Neurol 1988;23:339-46.

52. Shapira L, Houri Y, Barak V, Halabi A, Soskoine W A, Stabholz A.Human monocyte response to cementum extracts from periodontally diseasedteeth: effect of conditioning with tetracycline. J Periodontol1996;67:682-7.

53. Shapira L, Houri Y, Barak V, Soskolne W A, Halabi A, Stabholz A.Tetracycline inhibits' Porphyromonas gingivalis lipopolysaccharide-induced lesions in vivo and TNF α processing in vitro. J Periodontal Res1997;32:183-8.

54. Sharief M K, Ingram D A, Swash M. Circulating tumor necrosisfactor-alpha correlates with electrodiagnostic abnormalities inGuillain-Barre syndrome. Ann Neurol 1997;42:68-73.

55. Smith C S, Ortega G, Parker L, Shearer W T. Cyclosporin A blocksinduction of tumor necrosis factor-alpha in human B lymphocytes. BiochemBiophys Res Commun 1994;204:383-90.

56. Sonuner C, Schmidt C, George A, Toyka K V. Ametalloprotease-inhibitor reduces pain associated behaviour in mice withexperimental neuropathy. Neurosci Lett 1997;237:45-8.

57. Sorkin L S, Xiao W H, Wagner R, Myers R R. Tumour necrosisfactor-alpha induces ectopic activity in nociceptive primary afferentfibres. Neuroscience 1997;81:255-62.

58. Steinmeyer J, Daufeldt S, Taiwo Y O. Pharmacological effect oftetracyclines on proteoglycanases from interleukin-l-treated articularcartilage. Biochem Pharmacol 1998;55:93-100.

59. Stoll G, Jung S, Jander S, van der Meide P, Hartung H P. Tumornecrosis factor-alpha in immunomediated demyelination and Walleriandegeneration of the rat peripheral nervous system. Neuroimmunol1993;45:175-82.

60. Takao Y, Mikawa K, Nishina K, Maekawa N, Obara H. Lidocaineattenuates hyperoxic lung injury in rabbits. Acta Anaesthesiol Scand1996;40:318-25.

61. Teoh K H, Bradley C A, Galt J, Burrows H. Steroid inhibition ofcytokine-mediated vasodilation after warm heart surgery. Circulation1995;92:II347-53.

62. Tsukamoto T, Ishikawa M, Yamamoto T. Suppressive effects of TNF-α onmyelin formation in vitro. Acta Neurol Scand 1995;91:71-5.

63. van der Poll T, Jansen P M, Van Zee K J, Welborn M B r, de Jong I,Hack C E, Loetscher H, Lesslauer W, Lowry S F, Moidawer L L. Tumornecrosis factor-alpha induces activation of coagulation and fibrinolysisin baboons through an exclusive effect on the p55 receptor. Blood1996;88:922-7.

64. Villarroya H, Violleau K, Ben Younes-Chennoufi A, Baumann N.Myelin-induced experimental allergic encephalomyelitis in Lewis rats:tumor necrosis factor alpha levels in serum of cerebrospinal fluidinununohistochemical expression in glial cells and neurophages of opticnerve and spinal cord. J Neuroimmunol 1996;64:55-61.

65. Wagner R, Myers R R. Schwann cells produce tumor necrosis factoralpha: expression in injured non-injured nerves. Neuroscience1996;73:625-9.

66. Wagner R, Myers R R. Endoneurial injection of TNF-α producesneuropathic pain behaviours. Neuroreport 1996;7:2897-901.

67. Wasaki S, Sakaida I, Uchida K, Kiinura T, Kayano K, Okita K.Preventive effect of cyclosporin A on experimentally induced acute liverinjury in rats. Liver 1997; 17:107-14.

68. Wershil B K, Furuta G T, Lavigne J A, Choudhury A R, Wang Z S, GalliS J. Dexamethasone cyclosporin A suppress mast cell-leukocyte cytokinecascades by multiple mechanisms. Int Arch Allergy Immunol1995;107:323-4.

69. Yabuki S, Kawaguchi Y, Olmarker K, Rydevik B. Effects of lidocaineon nucleus pulposus-induced nerve root injury. Spine, 1998,23:29:2383-89

70. Zhu J, Bai X F, Mix E, Link H. Cytokine dichotomy in peripheralnervous system influences the outcome of experimental allergic neuritis:dynamics of MRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-α,TNF-beta, and cytolysin. Clin Iminunol Immunopathol 1997;84:85-94.

What is claimed is:
 1. A method of treating a nerve disorder mediated bynucleus pulposus in a mammal in need of such treatment wherein saidnerve disorder mediated by nucleus pulpous is caused by the liberationof TNF-α and compounds triggered by the liberation of or presence ofTNF-α comprising the step of administering a TNF-α inhibitor whereinsaid TNF-α inhibitor is a metalloproteinase inhibitor excludingmethylprenisolone to a mammal in need of such treatment therebyinhibiting TNF-α and treating said disorder.
 2. The method of claim 1,wherein the mammal is human.
 3. The method of claim 1, wherein the TNF-αinhibitor is administered systemically.
 4. The method of claim 1,wherein the TNF-α inhibitor is administered orally.
 5. The method ofclaim 1, wherein the TNF-α inhibitor is administered intramuscularly. 6.The method of claim 1, wherein the TNF-α inhibitor is administeredintravenously.
 7. The method of claim 1, wherein said nerve disorderinvolves pain.
 8. The method of claim 1, wherein said nerve disorder isa nerve root injury.
 9. The method of claim 8, wherein the mammal ishuman.
 10. The method of claim 8, wherein the TNF-α inhibitor isadministered systemically.
 11. The method of claim 8, wherein the TNF-αinhibitor is administered orally.
 12. The method of claim 8, wherein theTNF-α inhibitor is administered intramuscularly.
 13. The method of claim8, wherein the TNF-α inhibitor is administered intravenously.
 14. Themethod of claim 8, wherein said nerve disorder involves pain.
 15. Themethod of claim 1, wherein said nerve disorder presents as sciatica. 16.The method of claim 15, wherein the mammal is human.
 17. The method ofclaim 15, wherein the TNF-α inhibitor is administered systemically. 18.The method of claim 15, wherein the TNF-α inhibitor is administeredorally.
 19. The method of claim 15, wherein the TNF-α inhibitor isadministered intramuscularly.
 20. The method of claim 15, wherein theTNF-α inhibitor is administered intravenously.
 21. The method of claim1, wherein said nerve disorder is caused by a herniated disc.
 22. Themethod of claim 21, wherein the TNF-α inhibitor is administeredintravenously.
 23. The method of claim 21, wherein the TNF-α inhibitoris administered systemically.
 24. The method of claim 11, wherein theTNF-α inhibitor is administered orally.
 25. The method of claim 21,wherein the mammal is human.
 26. The method of claim 21, wherein theTNF-α inhibitor is administered intramuscularly.
 27. The method of claim21, wherein said nerve disorder involves pain.